Secondary prevention after ischemic stroke. Evolution over time in practice

Journal of Neurology

Volumn 252, Issue 1, 2005, Pages 14-20

  Girot, Marie ^a   Mackowiak Cordoliani, Marie Anne ^a   Deplanque, Dominique ^a   Hénon, Hilde ^a   Lucas, Christian ^a   Leys, Didier ^a  

^a UNIV LILLE   (France)

Author keywords

Ischemia; Prevention; Risk factors

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; STATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; NEUROLOGY; RECURRENCE; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 13144259685     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-005-0591-8     Document Type: Article

References (35)

1. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442
2. Hankey GJ, Warlow CP (1999) Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 354:1457-1463
3. Leys D, Bandu L, Hénon H, Lucas C, Mounier-Vehier F, Rondepierre P, Godefroy O (2002) Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology 59:26-33
4. Kannel WB, Wolf PA, Verter J (1983) Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 250:2942-2946
5. Tanne D, Shotan A, Goldbourt U, Haim M, Boyko V, Adler Y, Mandelzweig L, Behar S (2002) Severity of angina pectoris and risk of ischemic stroke. Stroke 33:245-250
6. Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani M-A, Lucas C, Bordet R (2002) Stroke prevention: management of modifiable risk factors. J Neurol 249:507-517
7. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335:827-838
8. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H and the LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
10. Progress Collaborative group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041
11. st century. Arch Intern Med 157:1177-1184
12. Di Mascio R, Marchioli R, Tognoni G (2000) Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 10:85-92
13. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
14. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V, Leys D (1999) Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 82:563-569
15. Redfern J, McKevitt C, Dundas R, Rudd AG, Wolfe CD (2000) Behavioral risk factor prevalence and lifestyle change after stroke: a prospective study. Stroke 31:1877-1881
16. Qureshi AI, Suri MF, Guterman LR, Hopkins LN (2001) Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 161: 1621-1628
17. Ruland S, Raman R, Chaturvedi S, Leurgans S, Gorelick PB (2003) Awareness, treatment, and control of vascular risk factors in African Americans with stroke. Neurology 60:64-68
18. EUROASPIRE Study Group. EUROASPIRE (1997) A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18:1569-1582
19. EUROASPIRE I and II Group (2001) Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357:995-1001
20. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni Mhurchu C, Clark T (1999) 1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21:1009-1060
21. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
22. American Diabetes Association (1997) clinical practice recommendations 1997. Diabetes Care 20:1-70
23. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106
24. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
25. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1:1215-1220
26. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321:501-507
27. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13
28. Bogousslavsky J, Kaste M, Skyhoj Olsen T, Hacke W, Orgogozo JM (2000) Risk factors and stroke prevention. European Stroke Initiative (EUSI). Cerebrovasc Dis 10 3:12-21
29. Guidelines for the management of transient ischemic attacks (1994) From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke 25:1320-1335
30. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL (1999) AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30:2502-2011
31. Summary of the second report of the National Cholesterol Education Program (NCEP) (1993) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult treatment panel II). JAMA 269:3015-3023
32. Diabetes mellitus. Report of a WHO study group. World health Organization, 1985
33. Wannamethee G, Shaper AG (1992) Physical activity and stroke in British middle aged men. Br Med J 304: 597-601
34. Gotto AM Jr (1997) Cholesterol management in theory and practice. Circulation 16:4424-4430
35. Joseph LN, Babikian VL, Allen NC, Winter MR (1999) Risk factor modification in stroke prevention: the experience of a stroke clinic. Stroke 30:16-20